Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Let’s start with the cheapest, the yearly FIT, or fecal immunochemical test, which looks for fecal blood that might be caused ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

Cologuard is an at-home colon cancer screening kit that detects changes in genetic material indicating potential cancer or polyps. Medicare covers one kit per year under Original Medicare (Parts A and ...

Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the quarter, the fund ...

Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year ...

Shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) gapped down prior to trading on Wednesday after the company ...

Guardant Health stock jumped Thursday on an "impressive" third-quarter report following the launch of its cancer detection test, Shield.

QRG Capital Management Inc. grew its stake in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 13.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The ...